AEON Biopharma Inc. held a special meeting on January 21, 2026. Shareholders approved the proposals required to complete the transactions announced in November, including the remaining issuances related to the company's private investment in public equity $(PIPE)$ financing and the exchange of convertible notes held by Daewoong Pharmaceutical Co., Ltd. The Daewoong note exchange closed following shareholder approval, substantially reducing outstanding debt and simplifying the capital structure. The company expects to proceed with the second closing of the PIPE financing on or around January 27, 2026, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9629946) on January 21, 2026, and is solely responsible for the information contained therein.